Evidence Hub

Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study

C. Liefferinckx, B. Verstockt, A. Gils, M. Noman, C. van Kemseke, E. Macken, M. De Vos, W. van Moerkercke et al.

Journal of Crohn's & Colitis, 2019

152 participants · 93 citations

Abstract

BACKGROUND

Ustekinumab (UST) was recently approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Long-term real-world data are currently scarce in CD patients previously exposed to several biologics.

METHODS

This is an observational, national, retrospective multicenter study. Patients received intravenous UST ~ 6mg/kg at baseline, with 90mg subcutaneously thereafter every 8 weeks. Response and remission rates were assessed at week 8, 16 and 52.

RESULTS

Data from 152 patients were analysed. All patients were exposed at least one anti-TNFα agent, with 69.7 % even two anti-TNFα and vedolizumab. After one year, 42.1 % and 25.7% experienced clinical response and clinical remission, respectively; 38.8% and 24.3% achieved steroid-free clinical response and remission, respectively at one year. Thirty-eight point eight per cent of patients discontinued therapy during the 12 months of follow-up. Colonic location was predictive of clinical response at one year, while low BMI at baseline was a negative predictor of clinical remission. Resolution of arthralgia was associated with clinical response over time. De novo arthralgia were reported by 17.9% of patients at week 8 and 13.5% at week 52. No impact of ustekinumab on arthralgia was observed in patients with concomitant ankylosing spondyloarthritis (n=17). Others adverse events were reported in 7.2% of patients.

CONCLUSIONS

This real-world cohort study confirms the effectiveness of ustekinumab in CD patients…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 152 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free